DrugBiological
Efbemalenograstim alfa clinical trials
Also written F-627.
- studies test it
- 10
- open now
- 3
- in phase 3
- 3
- first study started
- 2012
Keep track of what changes. Save the efbemalenograstim alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2014 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 6
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
EVIVE Biotechnology (7) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Henan Cancer Hospital (1) · Shandong University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses efbemalenograstim alfa is read from its arms, and is right about nine times in ten.
Testing it · 10
- Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FNRecruitingPhase 2Henan Cancer HospitalNCT07187908Written as Efbemalenograstim alfa Injection
- Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy RegimenRecruitingPhase 2Shandong UniversityNCT06251947Written as Efbemalenograstim Alfa
- Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic CancerNot yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06134765Written as Bemalenograstim alfa
- Study to Compare the Efficacy and Safety of F-627 and GRAN®CompletedPhase 3EVIVE BiotechnologyNCT04174599Written as F-627
- Study of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyCompletedPhase 1EVIVE BiotechnologyNCT02527746Written as F-627
- Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyCompletedPhase 3EVIVE BiotechnologyNCT03252431Written as F-627
- Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyCompletedPhase 3EVIVE BiotechnologyNCT02872103Written as F-627
- A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyCompletedPhase 1/2EVIVE BiotechnologyNCT02522234Written as F-627 240 μg/kg
- Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyCompletedPhase 2EVIVE BiotechnologyNCT01648322Written as F-627
- A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.CompletedPhase 2EVIVE BiotechnologyNCT02521441Written as F-627
Given in every arm · 1 — efbemalenograstim alfa is usual care beside what is tested
Codes
What other systems call efbemalenograstim alfa · ClinicalTrials.gg INT002134
- MeSH (NLM) C000731753efbemalenograstim alfaOne source NLM
- UNII (FDA) 5UPW5HJW3OEFBEMALENOGRASTIM ALFAConfirmed FDA, NLM
- NCI Thesaurus C102854Efbemalenograstim alfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731753 | efbemalenograstim alfa | One source NLM |
| UNII (FDA) | 5UPW5HJW3O | EFBEMALENOGRASTIM ALFA | Confirmed FDA, NLM |
| NCI Thesaurus | C102854 | Efbemalenograstim alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.